CHM (ASX) Ann: AML patient achieves Complete Response in CHM CORE-NK trial

Originally posted by Steini: ↑

One of the problems IMU and CHM are facing is the market not understanding that the complete responses across all their platforms have been achieved as 3rd, 4th or even 5th line of treatment. We are not talking about cancer stage 1, it is stage 3/4 and death row.

Plus, as so important these days but not recognised by the market either is DURABILITY and speed. Achieving a CR after a month and the previous one still being a CR shows the importance and difference of both companies' technologies.

The gap between the progress / data and the falling valuations is widening day by day - at some stage someone has to step up and has to sell / tell the market or the industry leaders. There are hundreds of great results achieved and reported everyday worldwide, one has to stand up and has to trumpet those incredible results to the world - otherwise the dismal financial performance of IMU and RAD will continue.

I made a few suggestions to the board on Friday, not sure if any of the members cares but last week's sh demands were suddenly met, maybe some of the decision makers will have at least a look at it. Can't get worse, or can it?

If Hopper comes out with a 1c cap raising then we know who the weakest link is.

GLTA

Expand

Originally posted by Steini: ↑

... but generally the trial patients had lines of treatments before they were eligible for CHM / IMU trials.

Sydney, Australia, 13 September 2023: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the
“Company”), an Australian leader in cell therapy, today announced the execution of a clinical
study agreement with The University of Texas MD Anderson Cancer Center to support the
“ADVENT-AML” Phase 1B study, in which Chimeric’s off-the-shelf universal donor NK cell
therapy CHM 0201 will be evaluated in combination with standard of care therapy for patients
with newly diagnosed Acute Myeloid Leukemia (AML).
The ADVENT-AML (NCT05834244) study is designed to enroll up to 20 subjects with newly
diagnosed AML who are not eligible for intensive chemotherapy or allogeneic stem cell
transplant, following completion of a dose confirmation cohort assessing the safety of this
novel combination treatment in subjects with relapsed or refractory AML.
ADVENT-AML will be the first trial to evaluate the synergy of NK cell therapy in combination
with the current standard of care of Azacitidine with Venetoclax (AZA-VEN). As the trial
progresses beyond dose confirmation, it will also be the first trial to evaluate cellular therapy in
newly diagnosed AML patients.
The study, which has received IND clearance by the FDA and is expected to open to enrollment
at MD Anderson by year end 2023, will be led by Principal Investigator Abhishek Maiti MD,
Assistant Professor in the Department of Leukemia at MD Anderson.
Acute Myeloid Leukemia (AML) is the most common acute leukemia in adults with a median
age at diagnosis between 65-72 years. Despite treatment advances, patients who are not
eligible for intensive chemotherapy or allogeneic stem cell transplant patients have limited
therapeutic options. Outcomes for these high-risk subgroups are poor with median overall
survival (mOS) of 6 to 9 months in the newly diagnosed setting1 and 2.4 months for patients
with relapse or refractory disease². Consequently, novel therapies are urgently needed to
improve outcomes for patients with AML.
“This exciting new clinical trial aligns with the emerging evidence that cell therapies provide the
best clinical outcomes in the earliest line of treatment,” said Jason B Litten, MD, Chief Medical
Officer of Chimeric Therapeutics.
“By combining CHM 0201 with the current standard of care for AML patients we may be able to
significantly enhance the outcomes for these patients.”
Under the terms of the clinical study agreement, Chimeric will provide CHM 0201 study drug as
well as partial financial support for study. In addition to the modest financial support from
Chimeric, the study will be supported by grant funding from multiple funding sources including
Gateway for Cancer Researc

Expand

I generally like your posts Steini... but.....
Virtually every trial requires patients to have failed one or more lines of treatment. Errr... thats why they are enrolled on a Trial.
Also... please dont refer to patients who have stage 4 cancer, as being on "death row". Its cruel and disrespectful.
GLTAH

No.	Vol.	Price($)
40	26298938	0.3¢

No.

Vol.

Price($)

26298938

0.3¢

Price($)	Vol.	No.
0.4¢	9474957	10

Price($)

Vol.

No.

0.4¢

9474957

No.	Vol.	Price($)
40	26298938	0.003
16	13800507	0.002
10	50600000	0.001
0	0	0.000
0	0	0.000

No.

Vol.

Price($)

26298938

0.003

13800507

0.002

50600000

0.001

0.000

Price($)	Vol.	No.
0.004	9474957	10
0.005	14691167	22
0.006	13747410	16
0.007	4700000	4
0.008	8542434	6

Price($)

Vol.

No.

0.004

9474957

0.005

14691167

0.006

13747410

0.007

4700000

0.008

8542434

(20min delay)
Last 0.4¢		Change 0.000(0.00%)		Mkt cap ! $8.060M

Open	High	Low	Value	Volume
0.4¢	0.4¢	0.4¢	$69.39K	17.34M

I generally like your posts Steini... but.....Virtually every...

Lithium Universe leaps 40% after buying rights to flashy solar panel recycling tech

Many are concerned about global falling birthrates. This diverse stock has solutions

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

ASX Market Open: Shares down as Trump threatens 'real end' to Israel-Iran conflict | June 18

Almonty Industries – Now it is getting critical!

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

I generally like your posts Steini... but.....Virtually every...

Top Stories

Lithium Universe leaps 40% after buying rights to flashy solar panel recycling tech

Many are concerned about global falling birthrates. This diverse stock has solutions

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

ASX Market Open: Shares down as Trump threatens 'real end' to Israel-Iran conflict | June 18

Almonty Industries – Now it is getting critical!

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News